Stocks
IGM Biosciences IncIGMS
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing engineered IgM antibodies for cancer and autoimmune diseases. Its pipeline includes lead candidate carfilzomib-based therapies and bispecific antibodies, with early-stage data closely watched by investors. The company's platform aims to improve upon IgG-based treatments through enhanced complement activation and target binding.
Congressional Interest in IGM Biosciences Inc (IGMS)
1 member of Congress has disclosed 1 trade in IGM Biosciences Inc (IGMS), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading IGMS?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-10-23 | JOHN K. DELANEY | buy | $1K-$15K |